Skip to content

Impact of Genetic Polymorphisms on Sedation Depth and Remimazolam Dose-Response in Patients Undergoing Laparoscopic Cholecystectomy: A Candidate Gene Association Study

Impact of Genetic Polymorphisms on Sedation Depth and Remimazolam Dose-Response in Patients Undergoing Laparoscopic Cholecystectomy: A Candidate Gene Association Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099063
Enrollment
Unknown
Registered
2025-03-18
Start date
2023-12-26
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis or gallstones

Interventions

Remimazolan group:ntravenous infusion of remimazolan (6 mg/kg/h)

Sponsors

The First Affiliated Hospital of University of South China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Patients who signed informed consent for elective general anesthesia laparoscopic cholecystectomy; 2. Between 18 and 74 years old; 3. No history of surgery or allergies; 4. No history of drug abuse or addiction; 5. No history of trauma or blood transfusion; 6. ASA Level I or II; 7. chinese of han nationality.

Exclusion criteria

Exclusion criteria: 1. A history of drug and psychotropic substance dependence; 2. Abnormal function of important metabolic organs such as liver and kidney; 3. A history of hypertension, diabetes, coronary heart disease and other diseases; 4. A history of genetic system-related diseases; 5. A history of mental or psycho-related illness; 6. Have other diseases that may affect the results of the test.

Design outcomes

Primary

MeasureTime frame
Time required for MOAA/S score to decrease to 1 after intravenous remazolam intravenous pump (6 mg/kg/h);The time required for the PSI to drop to 60 at remazolam intravenous pump (6 mg/kg/h);

Countries

China

Contacts

Public ContactLiu Chengxi

The Second Affiliated Hospital of University of South China

502315177@qq.com+86 151 7341 1398

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026